A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis
Latest Information Update: 10 Oct 2025
At a glance
- Drugs GSK-3862995B (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Sponsors GSK
Most Recent Events
- 10 Oct 2025 New trial record